Treatment of Latent Tuberculosis Infection in HIV-Positive Patients

Preferred First-Line Regimens for HIV-Positive Patients

The Centers for Disease Control and Prevention (CDC) recommends 3 months of once-weekly isoniazid plus rifapentine (3HP) as a preferred regimen with strong evidence (moderate quality) for HIV-positive patients, offering excellent tolerability, shorter duration, and higher completion rates 1, 3
The CDC also recommends 4 months of daily rifampin as a preferred regimen with strong evidence for HIV-negative patients, though no specific evidence exists for HIV-positive persons 1, 2
The CDC conditionally recommends 3 months of daily isoniazid plus rifampin with low-quality evidence specifically for HIV-positive patients 1, 2

The CDC conditionally recommends 6 months of daily isoniazid with moderate evidence quality for HIV-positive patients 1, 2
The CDC conditionally recommends 9 months of daily isoniazid with moderate evidence quality, historically considered standard therapy 1, 2, 4

The CDC recommends that active tuberculosis disease must be definitively excluded through detailed history and physical examination, chest radiography, and bacteriologic studies (sputum cultures) before initiating any latent TB treatment regimen 5, 6

The CDC notes that drug-drug interactions with antiretroviral therapy are the primary concern when using rifampin or rifapentine in HIV-positive patients, and recommends reviewing current drug interaction guidance 1, 5
The CDC recommends that rifabutin may be substituted when rifampin interactions are problematic, though with less evidence 1, 6

The CDC recommends clinical evaluations at 2, 4, and 8 weeks to assess for adverse effects and hepatitis symptoms during the 3-month rifampin plus isoniazid regimen 6
The CDC recommends baseline liver function tests for HIV-positive patients before starting treatment 6

The American Thoracic Society recommends ensuring active TB is excluded before treatment to avoid acquired drug resistance if unrecognized active disease is present 1, 2
The CDC recommends verifying antiretroviral compatibility before prescribing rifamycin-based regimens to avoid treatment failure of HIV infection 1, 5